Tachycardia Detection Algorithm Discriminating VT and SVT
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current implantable cardioverter defibrillators face challenges in accurately distinguishing between supraventricular tachycardia (SVT) and ventricular tachycardia (VT), leading to inappropriate therapy delivery and potential battery inefficiency due to the similarity in tachycardia cycle lengths and retrograde conduction patterns.
Innovation Solution
A tachycardia detection algorithm utilizing dual-vector EGM sensing and morphology analysis to differentiate between treatable VT and non-treatable SVT rhythms by employing specific beat features and evidence accumulation on a beat-by-beat basis, allowing for appropriate therapy selection and minimizing the need for high-voltage shocks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If tachycardia detection relies on cycle length measurement alone, then detection simplicity is maintained, but discrimination accuracy between SVT and VT deteriorates
Solution Approach 1:
The patent segments the tachycardia analysis into multiple independent features: cycle length, morphology characteristics, and conduction patterns. By dividing the detection task into separate analytical components, the system achieves comprehensive discrimination without requiring excessive complexity in any single measurement parameter.
Solution Approach 2:
The patent transitions from one-dimensional cycle length measurement to multi-dimensional analysis by incorporating morphology features and conduction pattern assessment. This dimensional expansion enables accurate SVT/VT discrimination while maintaining algorithmic efficiency through structured feature evaluation.
2Reliability
If high-voltage cardioversion shocks are delivered to terminate tachycardia, then therapy effectiveness is improved, but battery consumption and patient discomfort increase
Solution Approach 1:
The patent performs preliminary classification of tachycardia type (SVT vs. VT) using morphology and conduction analysis before delivering therapy. This preliminary action enables selection of appropriate therapy intensity, avoiding unnecessary high-voltage shocks for SVT cases and preserving battery charge while maintaining termination effectiveness for true VT cases.
Solution Approach 2:
The patent changes the therapy delivery parameter based on detected tachycardia characteristics. By adjusting shock voltage and energy levels according to the classified arrhythmia type, the system optimizes battery consumption while ensuring adequate therapy effectiveness for treatable conditions.
3Reliability
If aggressive therapy is applied to all detected tachycardias, then termination success rate is improved, but inappropriate treatment of SVT increases
Solution Approach 1:
The patent applies local quality by tailoring therapy intensity and type to the specific characteristics of each detected tachycardia. SVT cases receive appropriate conservative management or targeted pacing, while VT cases receive aggressive anti-tachycardia pacing or cardioversion, ensuring each patient receives the locally optimal treatment for their specific condition.
Solution Approach 2:
The patent changes therapy parameters based on tachycardia classification. By adjusting treatment aggressiveness according to the detected rhythm type and morphology features, the system maximizes termination success for treatable arrhythmias while avoiding harmful aggressive therapy for non-treatable SVT cases.
Data Source
AI summary
A medical device and associated method for discriminating cardiac events includes determining whether a first match score is within a first match zone having a first correlation with a non-treatable cardiac event, a second match zone having a second correlation with the non-treatable cardiac event less than the first correlation, a third match zone having a first correlation with a treatable cardiac event, and a fourth match zone having a second correlation with the treatable cardiac event greater than the first correlation with the treatable cardiac event. In response to the first match score being within one of the first and second match zones, a determination is made whether consecutive match scores are within the first match zone and whether a break in the treatable cardiac event has occurred. Cardiac evidence is accumulated in response to determining whether a break has occurred and utilized to discriminate cardiac events.